Physician profile
Jeffery Berinstein
NPI 1023492519
$17,729.61
in general payments reported to CMS, 2019-2025
7 companies · $8,079 in 2025
The $8,079 reported for 2025 was more than what 92% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $53.00 · 2022: $7,167 · 2023: $183 · 2024: $2,248 · 2025: $8,079.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $9,625 · Food and Beverage: $853 · Travel and Lodging: $32.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $9,625.00 |
| Food and Beverage | $853.09 |
| Travel and Lodging | $32.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $5,820.00 | 2022 | |
| Abbvie INC. | $4,502.07 | 2022-2025 | Rinvoq |
| Boehringer Ingelheim Pharmaceuticals, INC. | $3,500.00 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $2,154.54 | 2024 | Entyvio |
| Celgene Corporation | $1,396.84 | 2021-2023 | Zeposia |
| Janssen Biotech, INC. | $269.78 | 2024-2025 | Tremfya |
| Pfizer INC. | $86.38 | 2023-2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffery Berinstein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.